The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes
Open Access
- 17 February 2011
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (3), 697-702
- https://doi.org/10.2337/dc10-1949
Abstract
OBJECTIVE: Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion. However, GLP-1 also improves endothelial function in diabetes. RESEARCH DESIGN AND METHODS: Sixteen type 2 diabetic patients and 12 control subjects received a meal, an oral glucose tolerance test (OGTT), and two hyperglycemic clamps, with or without GLP-1. The clamps were repeated in diabetic patients after 2 months of strict glycemic control. RESULTS: During the meal, glycemia, nitrotyrosine, and plasma 8-iso prostaglandin F2α (8-iso-PGF2a) remained unchanged in the control subjects, whereas they increased in diabetic patients. Flow-mediated vasodilation (FMD) decreased in diabetes, whereas GLP-1 increased in both groups. During the OGTT, an increase in glycemia, nitrotyrosine, and 8-iso-PGF2a and a decrease in FMD were observed at 1 h in the control subjects and at 1 and 2 h in the diabetic patients. In the same way, GLP-1 increased in both groups at the same levels of the meal. During the clamps, in both the control subjects and the diabetic patients, a significant increase in nitrotyrosine and 8-iso-PGF2a and a decrease in FMD were observed, effects that were significantly reduced by GLP-1. After improved glycemic control, hyperglycemia during the clamps was less effective in producing oxidative stress and endothelial dysfunction and the GLP-1 administration was most effective in reducing these effects. CONCLUSIONS: Our data suggest that during the meal GLP-1 can simultaneously exert an incretin effect on insulin secretion and a protective effect on endothelial function, reasonably controlling oxidative stress generation. The ability of GLP-1 in protecting endothelial function seems to depend on the level of glycemia, a phenomenon already described for insulin secretion.Keywords
This publication has 22 references indexed in Scilit:
- Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase AArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?Diabetes, 2010
- Four weeks of near‐normalization of blood glucose has no effect on postprandial GLP‐1 and GIP secretion, but augments pancreatic B‐cell responsiveness to a meal in patients with Type 2 diabetesDiabetic Medicine, 2008
- Simultaneous Control of Hyperglycemia and Oxidative Stress Normalizes Endothelial Function in Type 1 DiabetesDiabetes Care, 2007
- The Effects of Plasma Insulin and Glucose on Myocardial Blood Flow in Patients With Type 1 Diabetes MellitusJournal of the American College of Cardiology, 2005
- Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery diseaseAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profileAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.JCI Insight, 1993
- Atherogenesis: a postprandial phenomenon.Circulation, 1979